
Most popular posts
- What makes great boards great
- The fate of control
- March Madness and the availability heuristic
- When business promotes honesty
- Due diligence: mine, yours, and ours
- Alligator Alley and the Flagler (?!) Dolphins
- Untangling skill and luck in sports
- The Southeastern Growth Corridors
- Dead cats and iterative collaboration
- Empirical evidence: power corrupts?
- A startup culture poses unique ethical challenges
- Warren Buffett and after-tax returns
- Is the secret to national prosperity large corporations or start-ups?
- This is the disclosure gap worrying the SEC?
- "We challenged the dogma, and it was incorrect"
- Our column in the Tampa Bay Business Journal
- Our letter in the Wall Street Journal
Other sites we recommend
Medical Progress, Please
Holman Jenkins, writing in The Wall Street Journal, succinctly and perfectly describes the brilliance and, sometimes, serendipity involved in breakthrough entrepreneurship. From Medical Progress, Please:
How does a device like MelaFind come into the world? It begins when a small defense contractor specializing in computer vision is approached by pharmaceutical giants seeking objective ways to evaluate unguents for hair growth, wrinkle reduction or wound healing. An adviser to the small company, a world-famous dermatologist, pipes up: “Wound healing is cool, but if you really want to do something for humanity, help us detect melanomas.”
America having great capital markets, it’s possible to raise $130 million for a speculative venture.
In addition to extolling the wizardry of American medicine and the strength of our capital markets, Mr. Jenkins recounts some of the challenges faced during FDA approval by the current “wave of devices bringing artificial intelligence to bear on medical diagnosis.” The details Mr. Jenkins reports are a clear example of what our friend Rhys Williams has argued before Congress: in addition to streamlining its approval process the FDA needs to switch from the “zero defect” to the ”calculated risk” model.